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Abstract
Background: Cardiac diseases are one of the major causes of death worldwide with
increasing incidence rate per year, particularly in developing countries such as Sudan
owing to urbanization and changing lifestyle. Myocardial infarction is a consequence of
the imbalance between the heart blood supply and the required heart cell; this disorder
leads to necrosis ofmyocardium andmay cause death. It could be diagnosed by at least
two of the following criteria: chest pain, electrocardiography (ECG) elevation, and levels
on cardiac biomarkers. This study aimed to evaluate the efficiency of N-terminal pro-
B-type natriuretic peptide (NTproBNP) for the diagnosis of acute myocardial infarction
(AMI).
Methods: This analytical case–control hospital-based study was conducted on total
of 70 individuals, of which 40 participants were suspected of or diagnosed with
AMI,while30 healthy subjects were included as a control group. Three ml of venous
blood were collected in lithium heparin containers. Troponin I (TnI) as a cardiac
biomarker was measured by TOSOH AIA-360,while theNTproBNP level was detected
using I-Chroma II. Personal and clinical data were collected directly from each
participant usinga predesigned questionnaire.
Results: A significant increase in the TnI level (mean: 13.13 ± 18.9ng/ml) and NTproBNP
(mean: 5756.5 ± 8378.2pg/mL) in AMI patients were detected when compared with
control mean (0.02 ± 0.00ng/ml and 57.8 ± 42.32pg/mL, respectively).
Conclusions: NTproBNP gave a high sensitivity (87.5%), specificity (100%), positive
predictive value (100%), and negative predictive value (85.7%) in the diagnosis of AMI
when compared with another cardiac biomarker such as TnI.
Keywords: acute myocardial infarction, NTproBNP, troponin I, Medani Heart Center,
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1. Introduction
A cardiac disease refers to any disorder that affects the heart function by either min-
imizing or eliminating the heart output [1]. Cardiac diseases are caused either by
structural heart disorder or myocardium abnormalities such as myocardial infarction (MI)
[2]. An acute myocardial infarction (AMI) is a consequence of the imbalance between
the heart blood supply and the required heart cell. This disorder leads to necrosis
of the myocardium and may even cause death [1].MI is the most common cause of
death worldwide [3, 4]. The frequency of MI has increased over the last few decades
throughout several states of Sudan, which may be due to the increase in the prevalence
of risk factors such as underlying diseases and habits [5]. The symptoms of a cardiac
disease include chest pain and dyspnea due to the reduction of oxygen in myocardial
cells, whichis considered as a cardinal indication of AMI [6], and palpitations due to the
increase in oxygen demand. Other symptoms include headache and limb weakness
[7]. The diagnosis of cardiac diseases depends on the history, risk factor, clinical
examination, symptoms, laboratory investigation, chest radiology, electrocardiography
(ECG), and echocardiography (Echo) [8].
Moreover, AMI can be diagnosed by at least two of the following three criteria; first,
typical symptoms such as a history of chest pain; second, changes on the ECG, and
third, elevation on cardiac biomarkers [9]. The latter are specific elements produced by
the cardiac cells and increase in cardiac disorders. Cardiac biomarkers include troponin,
creatine kinase (CK), myoglobin [10, 11], and brain natriuretic peptides (BNPs) [12].Cardiac
troponin is a muscle-regulatory protein produced by a muscular cell present in skeletal
and heart muscles. Troponins are generally categorized into three types; troponin T,
troponin I (TnI), and troponin C [13]. For cardiac biomarkers, TnI is more sensitive and
specific than others troponins [14]. In AMI, the TnI rises in plasma after 4–8 hr of the
onset of the symptoms, reaches the peak at 12–24 hr, and then returns to normal within
7–10 days of AMI [15]. CK, on the other hand, is an enzyme consisting of two protein
subunits:muscle protein (M) and brain protein (B), and depending on the constituent, CK
has three isoenzymes; CKBB, CKMM, and CKMB [16].While CKBB is more abundant in
the brain cells, CKMM is more abundant in the muscular cells and CKMB in the cardiac
muscles [17]. CKMB is more sensitive and specific for the diagnosis of cardiac disease
than CKMM and CKBB [15].CKMB level in plasma increases after 4-8 hours of MI and
reaches the peak at 12 – 24 hours then return to the normal level within 2 – 3 days
(16). BNPs are polypeptides produced by myocardium in response to the increased wall
stress due to an increase in volume or pressure of blood, to reduce intravascular volume
DOI 10.18502/sjms.v15i3.7746 Page 248
Sudan Journal of Medical Sciences Abuagla M. Dafalla et al
by diuretics, vasopressin, and suppuration the sense of thirst (16). BNPs are secreted as
pro-hormone then activated by reacting with protease enzyme to cleave it into active
form BNP and inactive form NTproBNP(18). In the case of cardiac disease, both BNPs are
elevated, thus, measurement of plasma BNP and /or NTproBNP is a useful indicator for
cardiac diseases (16). The objective of the present study was to evaluate the efficiency
of N-terminal pro-B-type natriuretic peptide (NTproBNP) for the diagnosis of AMI.
2. Materials and Methods
This analytical case-control hospital-based study aimed to evaluate the efficiency of
NTproBNP for the diagnosis of AMI.
The study was conducted in Medani Heart Center, Sudan. A purposive sample was
collected from patients with AMI attending Medani Heart Center from April 2018 to
June 2019. A total of 70 individuals participated in this study, 40 were AMI cases and
30 were healthy individual as a control group. AMI cases were included according
to the final diagnoses by Medani Heart Center physicians. AMI patients with renal
failure or Biotin treatment were excluded. The control group was non-smokers, non-
obese, normotensive, non-diabetic and have no history of renal or cardiac diseases.
The demographic data were collected from each participant after final diagnosis using
a questionnaire included clinical remarks such as AMI symptoms, ECG, Echo and risk
factors.
2.1. Ethical consderion
Permission to carry out the study was obtained from the College of Graduate Studies,
Faculty of Medical Laboratory Sciences, University of Gezira and Ministry of Health,
Sudan. All enrolled patients were informed about the purpose of the study before
collection of specimens and consents for participation were taken.
2.2. Data variable, collection and criteria
Sex, age (Year) - TnI (ng/ml) - NTProBNP (pg/ml) – Risk factors - Clinical Diagnosis -
Echocardiogram – Electrocardiogram were the variables used and also the data were
collected using laboratory analysis, doctor’s report, other findings and data collection
form. Restricted criteria for eligibility of case and control (inclusion and exclusion criteria)
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was followed to reduce sources of bias.A purposive sample was used to determine the
sample size because there is no previous prevalence for AMI in Sudan.
2.3. Measurement of cardiac biomarkers
Three ml of blood specimen from each participant were collected in lithium heparin
anticoagulant tubes for laboratory analysis; plasma was separated into two new plain
containers and examined within 2 hrs. The laboratory work was done in Medani Heart
Center and Department of Clinical Chemistry, Faculty of Medical Laboratory Sciences,
University of Gezira. TOSOH AIA-360 automated machine (Germany) was used to
measure TnI levels while I-Chroma II immunofluorescence system (Korea) was used
to measure NTproBNP levels.
3. Data analysis
Collected data were analyzed by using suitable statistic software including SPSS com-
puter version 22 and Medical calculator program version 16. Calculation of sensitivity,




Positive predictive value = TP/TP+FP*100.
Negative predictive value = TN/TN+FN*100.
TP: true positive - FP: false positive - TN: true negative -FN: false negative.
4. Results
4.1. Demographics of AMI subjects
This study enrolled 40 patients with AMI, among whom 62.5% were male, 45% diabetic,
40% hypertensive, 25% smokers, 25% obese,97.5% has no history of cardiac diseases.
Patients with age group above 59 years constituted 50% as shown in Table (1).
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4.2. Performance of NTproBNP and TnI
Total positive results of NTproBNP and TnI were 35/40 and 32/40, respectively. Sensi-
tivity, specificity, positive and negative predictive values of NTproBNP and TnI of AMI
patients and control were shown in Table 2.
4.3. Biomarkers levels
Plasma levels of NTproBNP and TnI were significantly detected among AMI patients;
the level of NTproBNP ranged from15 to 30000 with mean of 5756.5 pg/ml while TnI
recorded from 0.015 to 50 with mean of 13.1 ng/ml(Table 3).
4.4. Biomarkers results related to ECG and Echo
Positive ECG was recorded with 26 patients of 32 TnI positive and with 27 patients of 35
NTproBNP positive. While, less sensitively positive Echo were obtained with 20 patients
of 32 TnI positive, and with 21 patients of 35 NTproBNP positive Table 4.Measuring of
NTproBNP and TnI results using Area Under the Curve AUC according to ECG as the
gold standard method shown in Table 5, Figure (1).
TABLE 1: Characteristics of acute myocardial infarction patients.
N %
Sex Male 25 62.5
Female 15 37.5
Age/year <59 20 50
<59 20 50
Diabetes Diabetic 18 45
Non-diabetic 22 55
Chest pain Yes 40 100
No 0 0
Hypertension Yes 16 40
No 24 60
Smoking Yes 10 25
No 30 75
History of cardiac disease Yes 1 2.5
No 39 97.5
ECG STEMI 32 80
Non-STEMI 8 20
Obesity Obese 10 25
Non-Obese 30 75
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TABLE 2: Performances of NTproBNP and TroponinIamong cases and control.










NTproBNP Positive 35 0 87.5 100 100 85.7
Negative 5 30
TnI Positive 32 0 80 100 100 78.9
Negative 8 30
TABLE 3: Levels of NTproBNP (pg/ml)and Troponin I (ng/ml) among40 cases of AMI patients and 30 control
subjects
NO Mean SD p.value
NTproBNP Case 40 5756.5 8378.2 0.00
Control 30 57.8 42.3
TnI Case 40 13.1 18.9 0.00
Control 30 0.02 0.000
TABLE 4: Relationship between the results of Troponin I and NTproBNP with ECG and Echo
TnI /NTproBNP ECG Total
Positive Negative
NTproBNP Positive 27 8 35
Negative 5 0 5
TnI Positive 26 6 32
Negative 6 2 8
Echo
Positive Negative
NTproBNP Positive 21 14 35
Negative 3 2 5
TnI Positive 20 12 32
Negative 4 4 8





Positive group 𝑎 32 (45.71%)
Negative group 𝑏 38 (54.29%)
Area under the ROC curve for TnI 0.827
Area under the ROC curve for NTproBNP 0.817
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5. Discussion
MI is a consequence of the imbalance between heart blood supply and the heart cell
needs; this disorder leads to necrosis of the myocardium and may cause death (1). It is
diagnosed by at least two of three of the following criteria; firstly, chest pain, secondly
changes on the ECG, and thirdly elevation on cardiac biomarkers (9).
From this study, chest pain was recorded with all AMI patients, male patients more
frequently than females with a percentage of 62%.On the other hand, the age group
above and below 59 years were equally stated, these findings were in agreement with
a study done by Ahmed in Sudan(19).Diabetes mellitus and hypertension as risk factors
in the current study were observed in 45 % and 40% from AMI cases, this threat could
be decreased by routine follow up of patients and establishment of specialized centers
for care.
From the results, smokers were less than non-smokers; this was in concord with
a similar study(20) and in contrast with Elkhader et al(21).According to the clinical
diagnosis, 80% of AMI patients were ST-Elevation Myocardial Infarction (STEMI), this
result was near to the percentage concluded byAbdallah in Sudan(22).In the current
study, each of TnI andNTproBNP had significant values in the diagnosis of AMI in studied
patients, same findings were reported in the UK(23) and USA(24), however, in our study
12.5% (5/40) and 20% (8//40) of suspected cases gave insignificant concentrations for
NTproBNP and TnI,respectively.NTproBNP values were highly sensitive when compared
withTnI according to ECG and Echo, this result differs with those done byDimiati et al. in
Indonesia who foundTnI wasmore sensitive(25).The rea under ROC curve for NTproBNP
was (0.817) and for TnI equal (0.827) according to ECG as a gold standard method, this
indicates that each of the studied biomarkers had a good performance in the diagnosis
of AMI.
6. Conclusions
The NTproBNP had high sensitivity, specificity, positive predictive value and negative
predictive value when compared with TnI in the diagnosis of AMI.
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